This trial is active, not recruiting.

Condition onychomycosis of toenails
Treatment a fungal nail treatment
Sponsor Reckitt Benckiser Healthcare (UK) Limited
Collaborator Intertek
Start date November 2015
End date March 2017
Trial size 60 participants
Trial identifier NCT02546258, NPD810


This is a prospective, open label, non-comparative clinical investigation to evaluate the performance of a Fungal Nail Treatment on the visual signs of onychomycosis.

The Fungal Nail Treatment is a CE Marked Class I Medical Device and is commercially available as an over-the-counter product.

The ability of the Fungal Nail Treatment to treat the visual signs of mild fungal toenail infections will be determined by a reduction in the surface area of the infection over time. This will be assessed through visual quantification of the infected area from baseline, as measured by image analysis, throughout the treatment period, where subjects will follow instructions for use on the product pack and self-treat for the duration of the investigation or until their condition has resolved. Both subject and podiatrist will assess the improvement of signs and symptoms of the target nail.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Marketed treatment of Fungal Nail Follow instructions on pack
a fungal nail treatment Funagl Nail Treatment
treats the signs of mild fungal nail infections

Primary Outcomes

Percentage reduction of the surface area of infection over time using image analysis
time frame: 40 weeks

Secondary Outcomes

Percentage reduction of the surface area of infection over time from baseline to week 4 using image analysis
time frame: 4 weeks
The proportion of subjects whose fungal nail infection has resolved
time frame: 40 weeks

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Informed consent has been obtained. - Age between 18 years to 65 years inclusive. - Gender: male and female subjects. - Subjects with visual signs of MILD fungal nail infection present on at least one big toenail or with fungal nail infection on one other toenail on the same foot, in addition to the target big toenail (condition of other foot not relevant) as per podiatrist visual assessment. - Subjects with no more than 50% surface area of the target big toenail visually affected, from the leading distal edge, as assessed by the podiatrist. Exclusion Criteria: - Subjects with moderate to severe fungal toenail infection, on either big toenail, as determined by podiatrist assessment. - Subjects with fungal nail infection on more than two toenails on their target foot. - Subjects reporting presence of visual symptoms of fungal toenail infection for more than five years.

Additional Information

Official title A Prospective, Open Label, Non-comparative Clinical Investigation to Evaluate the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis
Principal investigator Rashid Haye, MBBS MD
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Reckitt Benckiser Healthcare (UK) Limited.